Annual Total Long Term Liabilities
$3.08 B
+$146.07 M+4.97%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual total long term liabilities is currently $3.08 billion, with the most recent change of +$146.07 million (+4.97%) on 31 December 2023. During the last 3 years, it has risen by +$1.28 billion (+70.74%). ALNY annual total long term liabilities is now at all-time high.ALNY Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$2.95 B
-$5.43 M-0.18%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly total long term liabilities is currently $2.95 billion, with the most recent change of -$5.43 million (-0.18%) on 30 September 2024. Over the past year, it has dropped by -$103.13 million (-3.38%). ALNY quarterly long term liabilities is now -4.83% below its all-time high of $3.10 billion, reached on 31 March 2024.ALNY Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +5.0% | -3.4% |
| 3 y3 years | +70.7% | +40.2% |
| 5 y5 years | +3202.6% | +407.5% |
ALNY Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +70.7% | -4.8% | +40.2% |
| 5 y | 5 years | at high | +3202.6% | -4.8% | +407.5% |
| alltime | all time | at high | >+9999.0% | -4.8% | >+9999.0% |
Alnylam Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.95 B(-0.2%) |
| June 2024 | - | $2.96 B(-4.7%) |
| Mar 2024 | - | $3.10 B(+0.6%) |
| Dec 2023 | $3.08 B(+5.0%) | $3.08 B(+0.9%) |
| Sept 2023 | - | $3.06 B(+1.1%) |
| June 2023 | - | $3.02 B(+1.5%) |
| Mar 2023 | - | $2.98 B(+1.4%) |
| Dec 2022 | $2.94 B(+24.5%) | $2.94 B(+3.8%) |
| Sept 2022 | - | $2.83 B(+13.4%) |
| June 2022 | - | $2.50 B(+2.9%) |
| Mar 2022 | - | $2.43 B(+2.8%) |
| Dec 2021 | $2.36 B(+30.7%) | $2.36 B(+12.0%) |
| Sept 2021 | - | $2.11 B(+0.2%) |
| June 2021 | - | $2.10 B(+14.6%) |
| Mar 2021 | - | $1.83 B(+1.6%) |
| Dec 2020 | $1.81 B(+199.0%) | $1.81 B(+12.0%) |
| Sept 2020 | - | $1.61 B(+1.4%) |
| June 2020 | - | $1.59 B(+169.0%) |
| Mar 2020 | - | $591.10 M(-2.1%) |
| Dec 2019 | $603.85 M(+546.9%) | $603.85 M(+3.8%) |
| Sept 2019 | - | $581.67 M(-7.8%) |
| June 2019 | - | $630.61 M(+98.4%) |
| Mar 2019 | - | $317.85 M(+240.5%) |
| Dec 2018 | $93.34 M(+11.1%) | $93.34 M(+22.8%) |
| Sept 2018 | - | $76.03 M(+38.4%) |
| June 2018 | - | $54.93 M(+3.7%) |
| Mar 2018 | - | $52.95 M(-37.0%) |
| Dec 2017 | $84.05 M(-60.1%) | $84.05 M(-57.6%) |
| Sept 2017 | - | $198.40 M(-2.1%) |
| June 2017 | - | $202.59 M(-2.2%) |
| Mar 2017 | - | $207.24 M(-1.7%) |
| Dec 2016 | $210.89 M(+253.3%) | $210.89 M(-2.4%) |
| Sept 2016 | - | $216.18 M(+1.4%) |
| June 2016 | - | $213.10 M(+246.3%) |
| Mar 2016 | - | $61.53 M(+3.1%) |
| Dec 2015 | $59.70 M(+24.4%) | $59.70 M(+4.0%) |
| Sept 2015 | - | $57.43 M(+3.3%) |
| June 2015 | - | $55.57 M(+7.7%) |
| Mar 2015 | - | $51.59 M(+7.5%) |
| Dec 2014 | $47.99 M | $47.99 M(+91.7%) |
| Sept 2014 | - | $25.03 M(-31.7%) |
| June 2014 | - | $36.65 M(-11.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $41.49 M(-56.9%) |
| Dec 2013 | $96.32 M(-8.4%) | $96.32 M(+1.4%) |
| Sept 2013 | - | $95.03 M(-6.2%) |
| June 2013 | - | $101.32 M(-8.1%) |
| Mar 2013 | - | $110.27 M(+4.9%) |
| Dec 2012 | $105.12 M(+26.8%) | $105.12 M(+16.2%) |
| Sept 2012 | - | $90.43 M(+23.7%) |
| June 2012 | - | $73.13 M(-4.1%) |
| Mar 2012 | - | $76.28 M(-8.0%) |
| Dec 2011 | $82.93 M(-37.6%) | $82.93 M(-6.2%) |
| Sept 2011 | - | $88.42 M(-14.8%) |
| June 2011 | - | $103.74 M(-16.4%) |
| Mar 2011 | - | $124.14 M(-6.7%) |
| Dec 2010 | $132.99 M(-31.0%) | $132.99 M(-12.8%) |
| Sept 2010 | - | $152.53 M(-11.7%) |
| June 2010 | - | $172.67 M(-10.5%) |
| Mar 2010 | - | $193.00 M(+0.2%) |
| Dec 2009 | $192.69 M(-23.9%) | $192.69 M(-9.3%) |
| Sept 2009 | - | $212.53 M(-8.3%) |
| June 2009 | - | $231.84 M(-7.8%) |
| Mar 2009 | - | $251.53 M(-0.6%) |
| Dec 2008 | $253.10 M(+19.9%) | $253.10 M(-7.5%) |
| Sept 2008 | - | $273.60 M(-0.6%) |
| June 2008 | - | $275.15 M(+38.6%) |
| Mar 2008 | - | $198.53 M(-6.0%) |
| Dec 2007 | $211.15 M(+1227.4%) | $211.15 M(-6.0%) |
| Sept 2007 | - | $224.70 M(+1591.8%) |
| June 2007 | - | $13.28 M(-3.9%) |
| Mar 2007 | - | $13.81 M(-13.2%) |
| Dec 2006 | $15.91 M(-12.0%) | $15.91 M(-12.7%) |
| Sept 2006 | - | $18.22 M(+10.9%) |
| June 2006 | - | $16.44 M(+4.2%) |
| Mar 2006 | - | $15.78 M(-12.7%) |
| Dec 2005 | $18.09 M(+35.1%) | $18.09 M(+48.5%) |
| Sept 2005 | - | $12.18 M(-2.2%) |
| June 2005 | - | $12.45 M(-4.9%) |
| Mar 2005 | - | $13.10 M(-2.2%) |
| Dec 2004 | $13.39 M(-76.9%) | $13.39 M(+22.6%) |
| Sept 2004 | - | $10.92 M(+20.1%) |
| June 2004 | - | $9.09 M(-87.1%) |
| Mar 2004 | - | $70.23 M(+21.0%) |
| Dec 2003 | $58.05 M(+221.0%) | $58.05 M |
| Dec 2002 | $18.08 M | - |
FAQ
- What is Alnylam Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual total long term liabilities year-on-year change?
- What is Alnylam Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Alnylam Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of ALNY is $3.08 B
What is the all time high annual total long term liabilities for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual total long term liabilities is $3.08 B
What is Alnylam Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, ALNY annual total long term liabilities has changed by +$146.07 M (+4.97%)
What is Alnylam Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of ALNY is $2.95 B
What is the all time high quarterly long term liabilities for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly total long term liabilities is $3.10 B
What is Alnylam Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, ALNY quarterly total long term liabilities has changed by -$103.13 M (-3.38%)